TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

NCT06676449 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

432

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Carcinoma
Radiotherapy
Immunotherapy

Interventions

DRUG: Immunotherapy
DRUG: chemotherapy: Paclitaxel/Cisplatin or other guideline recommended regimens
RADIATION: TDLN-sparing RT

Sponsor

Fudan University